Contemporary, Core-Lab Assessed, Acute Clinical Outcomes from 2000+ Patients with Mitral Regurgitation Treated with the 3rd and 4th Generation MitraClip™ Systems: Results from the EXPANDed Post Approval Studies

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Boston Scientific Corporation; Medtronic; W.L. Gore & Associates; Philips; Alleviant Medical; Innovheart; ACIST
• Equity/Stock(s)/Options - Indian Wells; InterShunt